The glycocalyx: a novel diagnostic and therapeutic target in sepsis
Top Cited Papers
Open Access
- 17 January 2019
- journal article
- review article
- Published by Springer Science and Business Media LLC in Critical Care
- Vol. 23 (1), 1-12
- https://doi.org/10.1186/s13054-018-2292-6
Abstract
The glycocalyx is a gel-like layer covering the luminal surface of vascular endothelial cells. It is comprised of membrane-attached proteoglycans, glycosaminoglycan chains, glycoproteins, and adherent plasma proteins. The glycocalyx maintains homeostasis of the vasculature, including controlling vascular permeability and microvascular tone, preventing microvascular thrombosis, and regulating leukocyte adhesion. During sepsis, the glycocalyx is degraded via inflammatory mechanisms such as metalloproteinases, heparanase, and hyaluronidase. These sheddases are activated by reactive oxygen species and pro-inflammatory cytokines such as tumor necrosis factor alpha and interleukin-1beta. Inflammation-mediated glycocalyx degradation leads to vascular hyper-permeability, unregulated vasodilation, microvessel thrombosis, and augmented leukocyte adhesion. Clinical studies have demonstrated the correlation between blood levels of glycocalyx components with organ dysfunction, severity, and mortality in sepsis. Fluid resuscitation therapy is an essential part of sepsis treatment, but overaggressive fluid therapy practices (leading to hypervolemia) may augment glycocalyx degradation. Conversely, fresh frozen plasma and albumin administration may attenuate glycocalyx degradation. The beneficial and harmful effects of fluid and plasma infusion on glycocalyx integrity in sepsis are not well understood; future studies are warranted. In this review, we first analyze the underlying mechanisms of glycocalyx degradation in sepsis. Second, we demonstrate how the blood and urine levels of glycocalyx components are associated with patient outcomes. Third, we show beneficial and harmful effects of fluid therapy on the glycocalyx status during sepsis. Finally, we address the concept of glycocalyx degradation as a therapeutic target.Keywords
Funding Information
- National Heart, Lung, and Blood Institute (R01 HL125371)
This publication has 78 references indexed in Scilit:
- Nanomechanics of the Endothelial Glycocalyx in Experimental SepsisPLOS ONE, 2013
- Mapping of matrix metalloproteinase cleavage sites on syndecan‐1 and syndecan‐4 ectodomainsThe FEBS Journal, 2013
- A new mechanism of action of sulodexide in diabetic nephropathy: inhibits heparanase-1 and prevents FGF-2-induced renal epithelial-mesenchymal transitionJournal of Translational Medicine, 2012
- Proteoglycan sequenceMolecular BioSystems, 2012
- Endothelial Glycocalyx: Permeability Barrier and MechanosensorAnnals of Biomedical Engineering, 2011
- Modulation of Syndecan-1 Shedding after Hemorrhagic Shock and ResuscitationPLOS ONE, 2011
- Plasma Restoration of Endothelial Glycocalyx in a Rodent Model of Hemorrhagic ShockAnesthesia & Analgesia, 2011
- The Glycocalyx of the Human Umbilical Vein Endothelial CellCirculation Research, 2009
- Heparanase Stimulation of Protease Expression Implicates It as a Master Regulator of the Aggressive Tumor Phenotype in MyelomaOnline Journal of Public Health Informatics, 2008
- The endothelial glycocalyx: composition, functions, and visualizationPflügers Archiv - European Journal of Physiology, 2007